Browse GPNMB

Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Detected at the cell surface in different types of cancers cells, including glioblastoma multiforme cells and most melanoma cell lines.
Domain PF00801 PKD domain
Function

Could be a melanogenic enzyme.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001818 negative regulation of cytokine production
GO:0030282 bone mineralization
GO:0031214 biomineral tissue development
GO:0032640 tumor necrosis factor production
GO:0032680 regulation of tumor necrosis factor production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
Molecular Function GO:0005178 integrin binding
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0050839 cell adhesion molecule binding
GO:1901681 sulfur compound binding
Cellular Component GO:0042470 melanosome
GO:0048770 pigment granule
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8857538: PTK6 promotes HIF1A stabilization
R-HSA-162582: Signal Transduction
R-HSA-8848021: Signaling by PTK6
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GPNMB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between GPNMB and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20570888MelanomaInhibit immunityDC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. We generated small interfering RNA-transfected B16F10 melanoma cells to completely knock down DC-HIL/Gpnmb expression, with no alteration in cell morphology, melanin synthesis, or MHC class I expression. This knockdown had no effect on B16F10 proliferation in vitro or entry into the cell cycle following growth stimulation, but it markedly reduced the growth of these cells in vivo following their s.c. injection into syngeneic immunocompetent (but not immunodeficient) mice. This reduction in tumor growth was due most likely to an augmented capacity of DC-HIL-knocked down B16F10 cells (compared with controls) to activate melanoma-reactive T cells as documented in vitro and in mice.
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GPNMB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GPNMB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3660.43
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8440.842
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.030.992
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8420.0851
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.6880.495
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2190.941
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.370.519
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.550.851
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2320.945
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7540.707
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4940.648
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1290.552
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GPNMB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GPNMB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GPNMB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GPNMB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GPNMB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GPNMB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GPNMB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGPNMB
Nameglycoprotein (transmembrane) nmb
Aliases HGFIN; glycoprotein NMB; glycoprotein nmb-like protein; osteoactivin; transmembrane glycoprotein HGFIN; Tran ......
Chromosomal Location7p
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GPNMB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GPNMB.
ID Name Drug Type Targets #Targets
DB05996Glembatumumab vedotinBiotechGPNMB1